Phase I trial, Quotient code: QSC205601

Phase I trial, Quotient code: QSC205601 [The full scientific title will be published within 30 months after the end of the trial]

Status

Active, not recruiting

Phases

Phase 1

Study type

Unknown

Source

ISRCTN

Registry ID

ISRCTN10521680

Enrollment

116

Registered

2022-02-01

Start date

2022-02-02

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended. Other

Interventions

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy human volunteer

Exclusion criteria

Exclusion criteria: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.

Design outcomes

Primary

Measure	Time frame
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.	—

Secondary

Measure	Time frame
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.	—

Countries

England, United Kingdom

Contacts

Public Contact- Novartis Study Director

novartis.email@novartis.com+41 61 324 11 11

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 14, 2026